ny-eso-1-specific t-cells in treating patients with advanced ny-eso-1-expressing sarcomas receiving palliative radiation therapy

Conditions: Sarcoma

Summary: this pilot, phase i trial studies the safety of cancer-testis antigen (ny-eso-1)-specific t cells (a type of immune cell) in treating patients with ny-eso-1-expressing sarcomas that have spread to other places in the body and are receiving palliative (relief of symptoms and suffering caused by cancer) radiation therapy. placing a modified gene for ny-eso-1 into white blood cells may help the body build an immune response to kill tumor cells that express ny-eso-1. palliative radiation therapy may help patients with advanced sarcoma live more comfortably. giving ny-eso-1-specific t cells following palliative radiation therapy may be a better treatment for patients with sarcomas.

primary objectives: i. to evaluate the safety and toxicity of ny-eso-1-specific t cells when given following high-dose, hypo-fractionated palliative radiation to patients with advanced ny-eso-1 expressing sarcomas. secondary objectives: i. to look for preliminary evidence of systemic efficacy of ny-eso-1-specific t-cell therapy following radiation on non-radiated tumors. ii. to determine whether radiation increases trafficking of adoptively transferred ny-eso-1-specific t cells by comparing tumor biopsy specimens from radiated and non-radiated tumors. outline: patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. patients then receive ny-eso-1-specific t cells intravenously (iv) over 60 minutes 2-3 days after completion of radiation therapy. after completion of study treatment, patients are followed up weekly for 2 weeks, at 4-6, 8, 10, and 12 weeks, and then for up to 6 months.

Eligibility criteria:
inclusion criteria: inclusion criteria for screening: * histopathological documentation of sarcoma * patients must express ny-eso-1 in their tumor by immunohistochemistry (ihc) (\> 5%) prior to leukapheresis * for leukapheresis, patients must meet the following criteria (any exceptions to this will require prior approval by the apheresis director and principal investigator \[pi\]): * pulse \> 45 or \< 120 * weight \>= 45 kg * temperature =\< 38° celsius (c) (=\< 100.4° fahrenheit \[f\]) * white blood cell count (wbc) \>= 2,000 * hematocrit (hct) \>= 30% * platelets \>= 75,000 inclusion criteria for treatment: * a diagnosis of a metastatic or unresectable sarcoma * patient must have a biopsy-accessible tumor to be radiated * patient must have consulted with a radiation oncologist who is planning radiation; their radiation oncologist should have documented plans to administer a dose of at least 30 gy in 5 or fewer fractions * human leukocyte antigen (hla) type a0201 or a2402 * zubrod (eastern cooperative oncology group \[ecog\]) performance status of '0-2' * all patients must have an electrocardiogram (ecg) within 2 weeks of starting conditioning * all patients must have an echo or multigated acquisition (muga) scan showing ejection fraction (ef) \> 50% and normal troponin and creatine kinase mb (ck mb) performed within 90 days of starting treatment exclusion criteria: exclusion criteria for screening: * patients who do not meet the above inclusion criteria will not receive leukapheresis exclusion criteria for treatment: * patients with a history of proven myocarditis, pericarditis, or endocarditis * pregnant women, nursing women, men and women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to study entry * inadequate renal function as indicated by serum creatinine \>= 1.5 times the upper limit of normal * inadequate liver function as indicated by total bilirubin \>= 1.5 times the upper limit of normal * aspartate aminotransferase (ast) and alanine aminotransferase (alt) \>= 2.5 times the upper limit of normal * active symptomatic congestive heart failure * clinically significant hypotension * newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 3 months will be allowed to participate * known untreated central nervous system (cns) metastasis * patients with systemic infections requiring antibiotics or chronic maintenance/suppressive therapy * patients receiving systemic anticancer therapy (chemotherapy, "biologics", immunotherapy) less than 2 weeks prior to starting radiation * clinically significant autoimmune disorders requiring on-going systemic immune-suppression for control * patients with acquired immunodeficiency syndrome (aids) or who are known to be human immunodeficiency virus (hiv) positive are not eligible for this study; testing may have been done up to 3 months prior to treatment * current treatment with steroids * known infection with hepatitis b virus (hbv) and hepatitis c virus (hcv); testing may have been done up to 3 months prior to treatment